{SOTEVTAMAB: A NEW APPROACH IN BLOOD DISEASES?

Sotevtamab, a novel bispecific antibody, is drawing significant interest within the oncology field. This unique agent at the same time targets CD3 and the CD19 antigen, connecting immune cells, specifically T cells, to diseased B cells. Early clinical data indicate potential in addressing resista